I
nflammatory bowel diseases (IBDs) comprising Crohn's disease (CD) and ulcerative colitis (UC) are chronic, relapsing conditions of the gastrointestinal tract affecting an estimated 1.6 million individuals in the United States. 1 With a peak incidence between the second and fourth decades of life, IBD is associated with significant morbidity including in many the need for lifelong immunosuppression, hospitalizations, and surgery. [1] [2] [3] [4] [5] In addition, the physical, emotional, and psychosocial impact of IBD poses substantial burden on patients' personal health experience adversely affecting their health-related quality of life (HRQoL). [6] [7] [8] With aging of the population and a negligible impact of IBD on mortality, the burden of IBD in the elderly is increasing. [9] [10] [11] [12] [13] [14] [15] Previous studies have examined phenotypic differences between older-onset IBD and younger-onset disease, concluding that the former is associated with more frequent isolated colonic involvement, and fewer stricturing and penetrating complications. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Comparison of the disease severity between the 2 groups has yielded more conflicting results with similar or higher rates of surgery in older patients with IBD, but less frequent use of immunosuppression and biological therapies. 11, 16, [19] [20] [21] The reduced use of immunosuppressive agents despite similar surgical rates (suggesting perhaps disease severity is not different between younger and older patients) raises the concern for potential undertreatment of active disease in older patients owing to concerns about side effects of medications. One can hypothesize that this hesitation in escalating medical therapy may result in inadequate control of symptoms, which, together with a diminished physical reserve, may lead to more profound impairments of HRQoL in the older patient with IBD. Few previous studies have compared general and disease-specific quality of life between older and younger IBD populations. Yet examining this difference could help accurately assess patients' subjective perception of their health state and suggest approaches to age-appropriate health care planning and personalized management of this lifelong disease.
Consequently, we performed this study in a large wellcharacterized prospectively recruited IBD cohort: (1) to compare the IBD-specific HRQoL in older patients with IBD with younger patients; (2) to analyze differences in general quality of life between the 2 populations; and (3) to define the impact of disease activity on quality of life among older and younger patients with IBD with the hypothesis that older patients may experience more negative consequences of persistent disease activity.
METHODS

Study Population
The study included patients recruited into the Prospective Registry in IBD Study at Massachusetts General Hospital. This is an ongoing prospective cohort of adult patients diagnosed with CD, UC, or IBD unspecified receiving care at the Massachusetts General Hospital Crohn's and Colitis center. [22] [23] [24] [25] On obtaining informed consent, a detailed questionnaire assessing disease and treatmentrelated information was completed by interview with a trained clinical research coordinator and confirmed by review of the medical records. The older IBD cohort was defined as individuals of at least 60 years at the time of assessment. This group was further subdivided into older patients with IBD with newly diagnosed disease and those who were diagnosed before age 60 years and had longstanding established disease. Younger patients with IBD less than 60 years of age comprised the control population.
Covariates and Outcomes
Detailed information was collected about age of onset, disease location and behavior (in CD), and disease extent (in UC) according to the Montreal classification, 26 and past and current medical and surgical history. Laboratory values at the time of enrollment included a measurement of hemoglobin, C-reactive protein, and erythrocyte sedimentation rate within 2 weeks of the enrollment visit. Each patient completed either the HarveyBradshaw index (HBI) 27 in CD or Simple Clinical Colitis Activity Index (SCCAI) 28 in UC and IBD unspecified.
The 2 primary outcomes for this study were IBD-specific and general quality-of-life scores. IBD-specific quality of life was assessed using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). 29 This questionnaire assesses quality of life over the previous week by scoring responses to 10 questions on a scale of 1 through 7; a total score of 70 represents perfect HRQoL. General quality of life was assessed using the Short Form-12 Questionnaire (SF-12). 30, 31 This 12-item questionnaire provides responses which can be combined, weighted, and scored to create 2 meta-scores, the physical health component scale score (PCS) and the mental health component scale score (MCS), each ranging from 0 to 100. 30 Higher values indicate a better perception of the general health. Both MCS and PCS have a mean of 50 and a SD of 10 in the general US population.
Statistical Analysis
Continuous variables were summarized using means and SDs and compared using the t test. Categorical variables were expressed as proportions and compared using the chi-square test with the Fisher's exact modification where appropriate. Univariate linear regression with SIBDQ as the outcome was performed to identify predictive variables. Multivariable regression models adjusting for these covariates and those previously described to impact HRQoL were used to examine the independent effect of older age on quality of life. A 2-sided P-value , 0.05 indicated statistical significance. Similar analyses were repeated for the SF-12 PCS and MCS scores separately. For the primary analysis, both scores were modeled as a continuous variable. In a sensitivity analysis, they were modeled as dichotomous scores with values below 50 (mean), indicating poor physical or mental quality of life. Prespecified stratified analysis was performed by type of IBD and by age of onset among the older IBD group. The influence of disease activity on HRQoL was examined by calculating the Pearson correlation coefficient between the SCCAI or HBI and SIBDQ in the 2 population groups. To examine the effect of IBD, the SF-12 PCS and MCS scores in the IBD cohort were compared with a group of healthy controls recruited for the registry. The study was approved by the Institutional Review Board of Partners Healthcare.
RESULTS
Study Population
Our study included 1607 patients with IBD who completed both quality-of-life questionnaires. Among these, 186 patients (99 CD, 87 UC) were older than 60 years (mean age 68 yr; range 61-94 yr), whereas the remaining 1421 younger patients with IBD (801 CD, 620 UC) had a mean age of 36 years (range 18-60 yr) ( Table 1 ). The older patients with IBD had a greater age at diagnosis (49 versus 26), longer disease duration (19 versus 10 yr), and were more likely to be male and former smokers (P # 0.001 for all). Older patients with CD were less likely to have penetrating disease behavior and perianal involvement and more likely to have isolated colonic disease (30% versus 24%). No differences were noted in UC extent between the 2 groups. As has been noted before, older patients with IBD were less likely to be ever users of immunomodulators (51% versus 62%, P , 0.001) or anti-tumor necrosis factor a biologics (29% versus 49%, P ¼ 0.027). At enrollment, there was no difference in disease activity between the older and younger IBD cohorts with similar HBI (3.7 versus 3.3, P ¼ 0.62) and SCCAI scores (2.6 versus 2.4, P ¼ 0.55). There was also no difference in the C-reactive protein (9.1 versus 7.9 mg/L), hemoglobin (13.6 g/dL versus 13.7 g/dL), and erythrocyte sedimentation rate (18.2 mm/h versus 22.5 mm/h) between the 2 groups.
One-third of the patients in the older IBD cohort were diagnosed after the age of 60 years (34%) with a mean age of diagnosis of 67 years and a disease duration of 4 years (newly diagnosed older IBD cohort). The remaining were diagnosed at a mean age of 39 years and had a disease for duration of 27 years (established older IBD cohort).
Comparison of IBD-specific and General HRQoL Between Elderly and Younger Patients
Among all included patients, the older IBD cohort had a modestly greater SIBDQ score when compared with younger patients with IBD (56.2 6 10.4 versus 54.4 6 11.3, P ¼ 0.04). Older patients were also more likely to have higher MCS scores on the SF-12 questionnaire (51.2 6 9.4 versus 48.1 6 9.8, P , 0.001) but a lower PCS score (46.6 6 10.3 versus 48.6 6 9.6, P ¼ 0.010) (Fig. 1) . These findings remained significant on multivariable analysis ( 
Comparison of Newly Diagnosed and Established Older Patients with IBD
There was no difference in the SIBDQ score between older patients with IBD with established disease and those with a recent diagnosis (57.8 versus 56.5, P ¼ 0.56). As well, there was no difference in the PCS or MCS components of the SF-12 except in older patients with UC, where those with a recent diagnosis had higher MCS scores than those with prolonged duration of disease (see Table 2 , Supplemental Digital Content 2, http://links.lww. com/IBD/B430). These findings remained on adjustment for other covariates.
Factors Associated with Quality of Life
On multivariable analysis, male sex (coefficient 2.33, 95% CI, 1.38-3.27) and a diagnosis of UC (1.79, 95% CI, 0.82-2.75) were associated with higher SIBDQ scores than women and those with CD, respectively. Disease activity at enrollment was the strongest inverse predictor of SIBDQ with each 1-point increase in the HBI or SCCAI scores being associated with a 12-point lower SIBDQ score (212.11, 95% CI, 213.14 to 211.10). In addition, use of steroids (21.80, 95% CI, 22.65 to 20.94), antitumor necrosis factor a biologics (20.80, 95% CI, 21.40 to 20.21), and ever smoking (22.10, 95% CI, 23.11 to 21.08) were independently associated with lower SIBDQ scores. In contrast, disease duration, location, extent, and phenotype did not predict HRQoL.
Given the strong impact of disease activity on SIBDQ, we examined if this correlation was stronger in older patients compared with younger patients under the hypothesis that impaired mobility and lower functional reserve in the elderly may lead to them experiencing worse quality of life for a given disease activity. However, we found a statistically similar correlation between disease activity and SIBDQ (rho 
DISCUSSION
The older patient represents a subgroup that is particularly vulnerable to the impact of chronic disease. As many as 1 in 5 patients with IBD are older than 60 years and this population is only expected to increase. 14, 16, 18, 32, 33 Although a growing body of literature has studied the older patient with IBD, the focus has been almost exclusively on differences in disease phenotype or in outcomes such as use of medications, hospitalizations, and surgery. [10] [11] [12] [13] [14] [15] [16] [17] [18] 32, 34 It is well recognized that an individual's perception of the impact of disease on quality of life is an important consequence of IBD. To our knowledge, few previous studies have examined IBD-specific and general quality of life in older patients with IBD.
One may hypothesize that older patients would be particularly vulnerable to some of the symptoms of IBD such as diarrhea and incontinence that may impair functional independence. However, an important and reassuring finding from our study was that this did not appear to be so with the SIBDQ actually being modestly higher in older patients with IBD compared with the younger ones. That this finding persisted on adjusting for disease phenotype and activity suggests that a more aggressive course in younger patients with newer onset disease is unlikely to explain this difference. We also found no difference in the quality of life between older patients with prolonged disease duration and newly diagnosed elderly patients with IBD. This lack of effect of disease duration was also demonstrated previously in a study where the mean quality of life scores for patients with CD of more than 20 years duration was not significantly different from those newly diagnosed. 35 Importantly, in our study, the contribution of disease activity to the SIBDQ was similar between older and younger patients, suggesting that similar improvements in disease-specific HRQoL may be obtainable through mitigation of disease activity in both groups. Comparative studies on which is the most effective and safe way to achieve this endpoint, be it medical or surgical treatment, are essential as achievement of remission, rather than the modality (medical or surgical) to achieve it is an important determinant of HRQoL. 36 Older patients demonstrated a significantly lower physical component score of the SF-12. In contrast, the mental component score of the SF-12 was better in older patients compared with younger individuals. This interesting dichotomy between the direction of effect of age on physical and mental quality has been reported for other chronic illnesses. In a large study of chronically ill individuals in Australia, compared with younger patients, older patients had a 6-point higher MCS score but an 8-point lower PCS score. 37 A few previous studies have found a similar association between age and quality of life in patients with IBD. 38 In a cross-sectional study of Israeli adult patients with IBD, Slonim-Nevo et al 39 reported SIBDQ and SF-36 MCS scores were positively associated with age, whereas SF-36 PCS scores were negatively associated with age. One explanation for the reduction in the PCS-12 score compared with the other scales used in the elderly is that a greater comorbidity burden in older patients may result in impairment of QOL that is not related to their underlying IBD but a reflection of the burden of illness. In addition, factors such as restricted mobility, depression, unemployment, widowed status, and reduction of functional independence may contribute to a lower perceived physical quality of life in older patients. 40, 41 This finding emphasizes that in delivering comprehensive care to the older patient with IBD, in addition to control of their IBD, it is essential for focus to be on these other factors that affect physical quality of life in these patients. The intriguingly higher MCS may relate to superior adaptation, resilience, and coping in older patients compared with younger individuals. 42, 43 As reported by other studies, disease activity was the strongest determinant of HRQoL in our cohort. 7, 35, 38, 44, 45 As well, consistent with previous studies, patients with CD had lower quality of life scores than those with UC. 7, 38, 44 In addition to disease activity, we identified associations between poor HRQoL and the female sex, steroid and anti-tumor necrosis factor a use, and tobacco history, while previous IBD-related surgery, disease duration, and 5-aminosalicylates use did not modified HRQoL measures. The lack of effect of previous surgical treatment is also consistent with Casellas et al 36 who showed that an improvement in IBDQ was achieved with attainment of remission through either medical or surgical interventions. 46 Although medical therapy has been consistently shown to improve HRQoL in IBD, 47 the evidence is not as robust for steroids where, as demonstrated by BlondelKucharski et al, 45 general HRQoL measured by SF-36 were worse for patients on steroids, regardless of dose or disease activity.
We readily acknowledge several limitations of our study. First, being based at a referral center, it may be susceptible to bias introduced by the greater severity of disease in our population. Second, while representing one of the largest cohorts to our knowledge to examine disease-specific and overall HRQoL in patients with IBD, there may be lower statistical power to determine the effect in specific subgroups. Third, we assessed disease activity and QOL at a single time point, which may not reflect longitudinal evolution of impact of disease. Fourth, we did not systematically screen for depression or evaluate physical functioning, frailty, and social support, which may all influence general HRQoL.
In conclusion, assessment of disease-specific and general HRQoL is an important part of IBD care. We provide reassurance that the older patient with IBD does not have a significantly lower IBD-specific quality of life but that such patients do have a lower general quality-of-life physical score, suggesting the impact of factors beyond IBD severity. Thus, comprehensive care of the older patient with IBD must include not only mitigation of disease activity but also assessment of factors contributing to impairment of physical quality of life and institution of appropriate interventions to improve patient outcomes.
